Top-News
Pharmazeutika Großbritannien

Hikma Pharmaceuticals News

Aktie
WKN:  A0HG69 ISIN:  GB00B0LCW083 US-Symbol:  HKMPF
23,20 €
+0,40 €
+1,75%
23.05.24 20:20:41
Handeln Depot/Watchlist
Aktienanzahl *
224,00 Mio.
Marktkapitalisierung *
5,02 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
FTSE 100
IR-Website
zur Website
*Stand: 27.01.2024

Hikma Pharmaceuticals News

03.10.23 - PR Newswire
Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US
Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US PR Newswire
18.09.23 - dpa-AFX
INDEX-MONITOR: Marks & Spencer und drei weitere Unternehmen nun im 'Footsie'
Im wichtigsten britischen Aktienindex werden an diesem Montag folgende vier Unternehmen aufgenommen: Der Bekleidungshersteller Marks & Spencer steigt in den FTSE 100 ...
29.12.22 - wallstreet:online Zentralredaktion
"Finanzwort des Jahres 2023": Disinflation: Diese Aktien könnten vom kommenden Megatrend profitieren
Nach einem Jahr mit zweistelligen Inflationsraten in vielen Ländern prognostiziert die UBS nun eine "starke" Disinflation für 2023. Welche Aktien dabei eine Rolle spielen könnten!
20.05.22 - The Motley Fool
Aktien: 1 Qualitätswert zum Ausverkaufspreis!
Aktuell korrigieren vor allem in den USA die Aktien- Kurse überproportional stark. Der Nasdaq-100-Index ist beispielsweise über 28 % gefallen (19.05.2022). Doch diese ...
29.04.22 - PR Newswire
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals PR Newswire
29.04.22 - PR Newswire
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals PR Newswire
29.03.22 - PR Newswire
Hikma Ventures invests in Tact.ai, an AI-powered customer engagement platform for life sciences companies
Hikma Ventures invests in Tact.ai, an AI-​powered customer engagement platform for life sciences companies PR Newswire
09.06.21 - PR Newswire
Hikma appoints Patrick Genestin to lead Generics Business Development
Hikma appoints Patrick Genestin to lead Generics Business Development PR Newswire
30.04.21 - PR Newswire
Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg
Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg Important new option for reversing opioid overdoses PR Newswire
28.04.21 - PR Newswire
Hikma announces exclusive agreement with AFT Pharmaceuticals for injectable non-opioid pain medication Combogesic® IV in the US
Hikma announces exclusive agreement with AFT Pharmaceuticals for injectable non-​opioid pain medication Combogesic® IV in the US PR Newswire
20.04.21 - PR Newswire
Hikma resumes launch of generic Advair Diskus®
Hikma resumes launch of generic Advair Diskus® PR Newswire
18.03.21 - PR Newswire
Hikma Pledges additional $40,000 to local US food banks and pantries in fight against hunger
Hikma Pledges additional $40,000 to local US food banks and pantries in fight against hunger Company's employee matching donation campaign has provided over 600,000 ...
18.02.21 - PR Newswire
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the ...
18.02.21 - PR Newswire
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the ...
13.01.21 - PR Newswire
Hikma's commitment to environmental performance recognised with "A-" rating in 2020 CDP Global Climate Change Report
Hikma's commitment to environmental performance recognised with "A-" rating in 2020 CDP Global Climate Change Report Improved rating elevates Hikma to global leadership ...
17.12.20 - PR Newswire
Hikma launches generic Advair Diskus® following FDA approval
Hikma launches generic Advair Diskus® following FDA approval PR Newswire
20.10.20 - PR Newswire
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-​to-administer medicine Adds ready-​to-administer injectable product to companies' ...
20.10.20 - PR Newswire
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-​to-administer medicine PR Newswire
03.09.20 - PR Newswire
Hikma receives favourable court ruling for its generic Vascepa®
Hikma receives favourable court ruling for its generic Vascepa® PR Newswire
26.08.20 - PR Newswire
Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership
Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership PR Newswire

Newssuche

Videos

newspaper
29.05.24
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »